Two Genetic Mutations Linked to Tumor Behavior in Thyroid Cancer Patients
CDC27 mutations may be associated with less aggressive behavior while SLC25A5 mutations may be associated with more aggressive behavior in papillary thyroid carcinomas.
CDC27 mutations may be associated with less aggressive behavior while SLC25A5 mutations may be associated with more aggressive behavior in papillary thyroid carcinomas.
The first-in-class compound CUDC-907, which is being tested for multiple myeloma and refractory lymphoma, may be promising for anaplastic thyroid cancer and poorly differentiated thyroid cancer.
Long-term recurrence rates appear to be low following the use of recombinant human thyrotropin for postoperative ablation in low-risk thyroid cancer.
Initiating treatment with the mTor inhibitor everolimus followed by the somatostatin analogue pasireotide may be beneficial in advanced thyroid cancer.
A new study has validated the American Thyroid Association sonographic pattern for selection of thyroid nodules undergoing ultrasound-guided fine needle aspiration.
Active surveillance in low-risk thyroid cancer may be better than immediate surgery in some patients.
Despite side effects, patients with differentiated thyroid cancer taking lenvatinib may experience better outcomes with close monitoring.
Current cut-offs for pregnancy-specific thyroid autoantibody positivity vary from by assay.
Liquid biopsy may prevent the need for unnecessary biopsies in patients with medullary thyroid carcinoma.
Half of the infants in the study had a delayed diagnosis of congenital hypothyroidism.
Please login or register first to view this content.